MedTrace Logo

Efficacy and Safety of Intravenous Treatment of Tuberculosis

NCT04150367 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 166

Last updated 2019-11-07

No results posted yet for this study

Summary

This Open-label, Randomized, Multicenter, Controlled, Parallel, Comparative Study will compare the efficacy and safety of intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment and the treatment with the oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment for Patients With Widespread Destructive Pulmonary Tuberculosis With Bacterial Excretion.

Conditions

  • Tuberculosis, Pulmonary

Interventions

DRUG

Isoniazid

Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.

DRUG

Rifampicin

Participants will get the dosage according to the instruction for use.

DRUG

Ethambutol

Participants will get the dosage according to the instruction for use.

DRUG

Rifampicin

Participants will get the dosage according to the instruction for use.

DRUG

Isoniazid

. Participants will get the dosage according to the instruction for use.

DRUG

Ethambutol

Participants will get the dosage according to the instruction for use.

Sponsors & Collaborators

  • Yuria-Pharm

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-03
Primary Completion
2018-07-14
Completion
2018-07-14

Countries

  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04150367 on ClinicalTrials.gov